Managing Cancer as a Chronic Illness
Altered tumor immune microenvironment (TIME) and longitudinal monitoring can help identify the possibility of cancer developing into chronic disease, and can determine the possibility of chronic cancer diseases that previously drug-resistant patients will become effective chronic cancer diseases due to precise combination immunotherapy that are originally drug-resistant patients but have become effective due to precise combination therapy.
Select TIL-like cells in blood by liquid biopsy
CellEnvision Biotech has a core technology – is a total solution platform that we have developed to combine AI imaging + living cell monitoring microscopy + 3D printing + microfluidic system for the Selection of Blood-TIL cells in blood by liquid biopsy, and co-cultured with primary cancer cells or CTM to dynamically monitor cytotoxicity efficacy for cell therapy or new drug development.
Positive case (TIL-like cells kill CTM spheroid):
By finding the tumor-associated antigen (TAA) on the TIL-like cells with cytotoxicity.
Negative case (CTM spheroid kills TIL-like cells):
By finding the tumor-specific antigen (TSA) on the tumor cells in the CTM spheroid.
Combining the strengths and advantages of Taiwan’s ICT manufacturing industry, we provide a high-throughput specific cell sorting platform with higher throughput (handing 106 cells < 1hr), faster sorting speed, higher recovery rate (>85%), higher activity (cell viability >90%) and high cost-effectiveness.
Photomask-free Digital-light Pattern Exposure Hydrogel in Self-assemble-cells-array ( SACA ) Chip for High-Throughput Cell Screening. This system can arrange millions of cells in the blood in a monolayer, and at the same time, identify specific cells through a fluorescent optical image recognition system for digital positioning. Then, 3D printing DLP Digital Light Processing technology is used to expose the hydrogel in a single spot. Within a non-calibrated area, specific cells will not be covered by immobilized hydrogel, and a large number of cells (Max: 106 cells/cm2) can be sorted and grabbed at one time for subsequent culture or molecular inspection and analysis.
Workflow of
Core Technology in Clinical
Clinical assessment and diagnosis
AI- immunofluorescence images for DTCs/ CTM detection
Healthy people can detect the presence or absence of disseminated tumor cells (DTCs) early to improve the cure rate. Cancer survivors can be proactive in detecting potential recurrence or new cancers by being aware of early changes and undergoing regular follow-up care.
Data analysis by the databank of CytoSCM
Tumor-associated macrophages & Lymphocytes with Single-cell multi-omics
Using minimal residual disease (MRD) as a means to establish a tumor immune cell database for early adjustment of treatment plans, rather than competing with the existing MRD companies in the market for predicting the probability of recurrence or detecting mutation genes for recurrence.
Monitoring the immune cell profiling of hot or cold tumors in TiME
longitudinal monitoring of tumor immune microenvironment (TiME) for the development of Immunotherapy Combination Strategies.
By analyzing the changes before and after the use of immunotherapy on tumor-associated immune cells, we will assist pharmaceutical companies in providing second-and third-line drugs for drug-resistant groups with concurrent treatments and the opportunity to convert them into first-line drugs.
Cell cultured and Cell therapy assessment
Recognize & Collect Neoantigen-reactive T cells
Negative selection for capturing TIL cells in blood to assist cell preparation manufacturers in cell therapy to increase the sensitivity of TIL, DC/CIK, while shortening the subsequent cell amplification culture time.
Clinical follow-up and scheduled checkups
Our business overseas
collaborations strategy partners
With patents approved in the United States (UChicago Medicine), Europe (Gustave Roussy Cancer Centre, France), Asia (Tokyo University; Institute of Information Technology and Management, Indian), and Taiwan, Cell Envision hopes to deliver even more positive results in the biotech field. The company has recently closed its seed funding round and will look to new territories like Europe and the United States following its presence in Asia.
